SM Tolaney

469 citations
40 papers · 323 · h-index 9

Impact in

  • Oncology top 10%
    • HER2/EGFR in Cancer Research
    • Cancer Immunotherapy and Biomarkers
    • Cancer Treatment and Pharmacology
    • PARP inhibition in cancer therapy
  • Cancer Research
    • Breast Cancer Treatment Studies
    • Cancer Genomics and Diagnostics

Papers in

  • Oncology 36
    • HER2/EGFR in Cancer Research 17
    • Cancer Treatment and Pharmacology 16
    • Lung Cancer Research Studies 7
    • Cancer Immunotherapy and Biomarkers 5
    • Colorectal Cancer Treatments and Studies 3
  • Pulmonary and Respiratory Medicine 30
    • Advanced Breast Cancer Therapies 24
Co-authors
Vassiliki Karantza (3 shared papers)Gursel Aktan (3 shared papers)D. Xing (3 shared papers)Sami Diab (3 shared papers)Kevin Kalinsky (4 shared papers)Soamnauth Misir (1 shared paper)LA Carey (5 shared papers)Martin Olivo (1 shared paper)
Journals
Cancer Research (26 papers)ESMO Open (5 papers)Annals of Oncology (4 papers)Journal of Clinical Oncology (2 papers)European Journal of Cancer (2 papers)
Partner nations
United StatesUnited KingdomSpain

In The Last Decade

SM Tolaney

37 papers receiving 317 citations

Peers

SM Tolaney
Comparison fields: 5 of 31
  • Oncology 287
  • Cancer Research 120
  • Pulmonary and Respiratory Medicine 123
  • Genetics 25
  • Immunology 47
Replace Marie-Pascale Graas with:
Marie-Pascale Graas Belgium
P. Schmid United Kingdom
Mahesh Shivhare United Kingdom
Vicente Carañana Spain
Anna Barbro Sætersdal Norway
Nadia Tosti Switzerland
Cecilie Bendigtsen Schirmer Norway
L Ryvo Israel
Ning Liao China
Danai Fimereli Belgium
SM Tolaney relative to Marie-Pascale Graas Belgium Marie-Pascale Graas's profile →
Citations per field
00.5×1.5×2.1×
Marie-Pascale Graas · 1×
Citations per year

Countries citing papers authored by SM Tolaney

Since Specialization
Citations

This map shows the geographic impact of SM Tolaney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by SM Tolaney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites SM Tolaney more than expected).

Fields of papers citing papers by SM Tolaney

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by SM Tolaney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by SM Tolaney. The network helps show where SM Tolaney may publish in the future.

Co-authors

The 25 scholars most cited alongside SM Tolaney, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with SM Tolaney Line = papers co-authored together SM Tolaney links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 40 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Abstract PD6-13: Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer
Cancer Research ·SM Tolaney, Kevin Kalinsky, Virginia Kaklamani, Claudio Savulsky, Martin Olivo, Gursel Aktan, PA Kaufman, D. Xing, A. Almonte, Soamnauth Misir, Vassiliki Karantza, Sami Diab
201856
2
Abstract S2-05: Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: Outcomes from CALGB 40603 (Alliance)
Cancer Research ·W. M. Sikov, DA Berry, CM Perou, Bhupender Singh, C. Cirrincione, SM Tolaney, George Somlo, ER Port, R Qamar, Keren Sturtz, Eleftherios P. Mamounas, Mehra Golshan, J.R. Bellon, Deborah Collyar, O Hahn, LA Carey, CA Hudis, EP Winer
201651
3
Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer
European Journal of Cancer ·SM Tolaney, Claudio Savulsky, Gursel Aktan, D. Xing, A. Almonte, Vassiliki Karantza, Sami Diab
201731
4
Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC)
Cancer Research ·SM Tolaney, WT Barry, CT Dang, DA Yardley, Beverly Moy, P. Kelly Marcom, KS Albain, HS Rugo, Matthew J. Ellis, Iuliana Shapira, Antonio C. Wolff, LA Carey, BA Overmoyer, AH Partridge, Hao Guo, CA Hudis, IE Krop, HJ Burstein, EP Winer
201322
5
MonarcHER: A randomized phase II study of abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer (ABC)
Annals of Oncology ·SM Tolaney, Andrew Wardley, Stefania Zambelli, John Hilton, Tiffany A. Troso-Sandoval, Francesco Ricci, S.-A. Im, S. B. Kim, S. Johnston, Arlene Chan, Shom Goel, Kristen Catron, Zhengyu Yang, Corona Gainford, Fabrice André
201919
6
Abstract P1-09-01: A phase 1b study of abemaciclib plus pembrolizumab for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC)
Cancer Research ·HS Rugo, Peter Kabos, MN Dickler, W. J. John, Ian C. P. Smith, Yi Lu, Suzanne R.L. Young, SM Tolaney
201814
7
Update on a phase I pharmacologic and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors.
Journal of Clinical Oncology ·J. H. M. Schellens, Geoffrey I. Shapiro, Anne C. Pavlick, Raoul Tibes, Suzanne Leijen, SM Tolaney, Iván Díaz-Padilla, Ramesh K. Ramanathan, Tim Demuth, J. Viscusi, J. Cheng, Raymond W. Lam, Yingru Xu, Amit M. Oza
201114
8
Abstract GS1-07: Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate, as ≥3rd-line therapeutic option for patients with relapsed/refractory metastatic triple-negative breast cancer (mTNBC): efficacy results
Cancer Research ·Aditya Bardia, Linda T. Vahdat, Jennifer R. Diamond, Kevin Kalinsky, Joyce O’Shaughnessy, R Moroose, SJ Isakoff, SM Tolaney, AD Santin, V Abramson, NC Shah, SV Govindan, Paul Maliakal, RM Sharkey, WA Wegener, D M Goldenberg, IA Mayer
201812
9
A phase II study of ixabepilone plus trastuzumab for metastatic HER2-positive breast cancer.
Cancer Research ·SM Tolaney, Julie Najita, W Chen, Jennifer Savoie, Marie Fornier, IE Krop, EP Winer, Craig A. Bunnell
200910
10
Abstract P5-15-02: Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer
Cancer Research ·SM Tolaney, Claudio Savulsky, Gursel Aktan, D. Xing, A. Almonte, Vassiliki Karantza, Sami Diab
20178
11
Abstract P1-19-01: A phase 2 study of abemaciclib in patients with leptomeningeal metastases secondary to HR+, HER2- breast cancer
Cancer Research ·SM Tolaney, Solmaz Sahebjam, Émilie Le Rhun, NU Lin, Melissa Bear, Zhengyu Yang, Yunqian Chen, CK Anders
20198
12
Abstract OT2-07-07: ATR inhibitor M6620 (formerly VX-970) with cisplatin in metastatic triple-negative breast cancer: Preliminary results from a phase 1 dose expansion cohort (NCT02157792)
Cancer Research ·ML Telli, Simon Lord, Emma Dean, Vandana G. Abramson, H-T. Arkenau, C. Murias, Carlos Becerra, Rui Tang, MS Penney, Jessica A. Pollard, G. Conboy, SZ Fields, Geoffrey I. Shapiro, SM Tolaney
20188
13
Abstract P4-13-25: Abemaciclib, an inhibitor of CDK4 and CDK6, combined with endocrine and HER2-targeted therapies for women with metastatic breast cancer
Cancer Research ·MP Goetz, Muralidhar Beeram, Thaddeus Beck, AK Conlin, EC Dees, MN Dickler, TL Helsten, PR Conkling, WJ Edenfield, DA Richards, P. Kellie Turner, Ning Cai, EM Chan, Shubham Pant, CH Becerra, Kevin Kalinsky, SL Puhalla, BN Rexer, HA Burris, SM Tolaney
20166
14
Abstract PD05-01: CALGB 40302: Fulvestrant with or without Lapatinib as Therapy for Hormone Receptor Positive Advanced Breast Cancer: A Double-Blinded, Placebo-Controlled, Randomized Phase III Study
Cancer Research ·HJ Burstein, WT Barry, Constance Cirrincione, HK Chew, SM Tolaney, Diana Lake, TJ Pluard, Kim T. Blackwell, EP Winer, CA Hudis
20106
15
358TiP Phase Ib/II study of antibody-drug conjugate, sacituzumab govitecan, in combination with the PARP inhibitor, talazoparib, in metastatic triple-negative breast cancer
Annals of Oncology ·Aditya Bardia, Laura M. Spring, Dejan Juric, Ann Partridge, Jennifer A. Ligibel, Irene Kuter, Jeffrey Peppercorn, Heather A. Parsons, Paula D. Ryan, Divya Chawla, Victoria Attaya, Donna M. Fitzgerald, Elene Viscosi, B. Lormill, Maria Shellock, B. Moy, SM Tolaney, Leif W. Ellisen
20205
16
P1-17-10: Cabozantinib (XL184) in Patients with Metastatic Breast Cancer: Results from a Phase 2 Randomized Discontinuation Trial.
Cancer Research ·SM Tolaney, Hovav Nechushtan, Regina Berger, Razelle Kurzrock, IG Ron, Patrick Schöffski, Ahmad Awada, CA Yasenchak, HA Burris, DA Ramies, XuChaoyan Shen, EP Winer
20115
17
Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer
ESMO Open ·Albert Grinshpun, Shan Ren, Noah Graham, M.K. DeMeo, Eileen Wrabel, John A. Carter, Nabihah Tayob, Alyssa Pereslete, E. Hamilton, Dejan Juric, EL Mayer, SM Tolaney, Ian E. Krop, Otto Metzger
20244
18
TBCRC 011: Targeting the androgen receptor (AR) for the treatment of AR+/ER-/PR- metastatic breast cancer (MBC).
Journal of Clinical Oncology ·Ayca Gucalp, SM Tolaney, SJ Isakoff, J. N. Ingle, M. C. Liu, LA Carey, K. L. Blackwell, H. S. Rugo, Lisle Nabell, A. Abbruzzi, José González, D. D. Giri, Sunita Patil, KN Feigin, Gabriella D’Andrea, M. Theodoulou, Pamela Drullinsky, Nancy T. Sklarin, C. Hudis, TA Traina
20114
19
353TiP HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally advanced or metastatic HER2+ breast cancer
Annals of Oncology ·Sara A. Hurvitz, Linda T. Vahdat, Nadia Harbeck, Antonio C. Wolff, SM Tolaney, Sherene Loi, Norikazu Masuda, Joyce O’Shaughnessy, Cassie Dong, Luke Walker, Evelyn Rustia, Virginia F. Borges
20204
20
Abstract GS3-02: Invasive disease-free survival and gene expression signatures in CALGB (Alliance) 40601, a randomized phase III neoadjuvant trial of dual HER2-targeting with lapatinib added to chemotherapy plus trastuzumab
Cancer Research ·IE Krop, DW Hillman, M-Y Polley, Maki Tanioka, Joseph F. Parker, L Huebner, N. Lynn Henry, SM Tolaney, Celeste Dang, Lyndsay Harris, DA Berry, CM Perou, Ann H. Partridge, EP Winer, LA Carey
20184

About SM Tolaney

SM Tolaney is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 40 papers that have together received 323 indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (24 papers), HER2/EGFR in Cancer Research (17 papers), Cancer Treatment and Pharmacology (16 papers), Breast Cancer Treatment Studies (8 papers), Lung Cancer Research Studies (7 papers), Cancer Immunotherapy and Biomarkers (5 papers), Cancer Genomics and Diagnostics (4 papers) and Colorectal Cancer Treatments and Studies (3 papers). The work is most often cited by research in Oncology (287 citations), Cancer Research (120 citations), Pulmonary and Respiratory Medicine (123 citations), Genetics (25 citations) and Immunology (47 citations). SM Tolaney has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Vassiliki Karantza, Gursel Aktan, D. Xing, Sami Diab, Kevin Kalinsky, Soamnauth Misir, LA Carey, Martin Olivo, Virginia Kaklamani and EP Winer. Their work appears in journals such as Cancer Research, ESMO Open, Annals of Oncology, Journal of Clinical Oncology and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marie-Pascale GraasBreakdown of academic impact, for papers by P. SchmidBreakdown of academic impact, for papers by Mahesh ShivhareBreakdown of academic impact, for papers by Vicente CarañanaBreakdown of academic impact, for papers by Anna Barbro SætersdalBreakdown of academic impact, for papers by Nadia TostiBreakdown of academic impact, for papers by Cecilie Bendigtsen SchirmerBreakdown of academic impact, for papers by L RyvoBreakdown of academic impact, for papers by Ning LiaoBreakdown of academic impact, for papers by Danai Fimereli